Article Information
History
- March 23, 2023.
Article Versions
- Version 1 (March 22, 2023 - 17:30).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Simeng Lin1,2,*,
- Eilis Hannon3,*,
- Mark Reppell4,
- Jeffrey F. Waring4,
- Nizar Smaoui4,
- Valerie Pivorunas4,
- Heath Guay4,
- Neil Chanchlani1,2,
- Claire Bewshea2,
- Benjamin Y H Bai5,6,
- Nicholas A Kennedy1,2,
- James R Goodhand1,2,
- Jonathan Mill3,*,
- Tariq Ahmad1,2,#,*,
- PANTS Consortium
- 1Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK
- 2Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK
- 3University of Exeter Medical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK
- 4AbbVie Inc., Chicago, IL, USA
- 5Genomics of Inflammation and Immunity Group, Wellcome Sanger Institute, Hinxton, UK
- 6Postgraduate School of Life Sciences, University of Cambridge, Cambridge, UK
- ↵#Address for correspondence
Tariq Ahmad, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, RILD building, Barrack Road, Exeter. EX2 5DW, UK, tariq.ahmad1{at}nhs.net
Posted March 23, 2023.
Whole blood DNA methylation changes are associated with anti-TNF drug concentration in patients with Crohn’s disease
